

Special Issue

New Insights into Targeted Drugs for Breast Cancer

Message from the Guest Editors

Over the last decade we have seen a rapid increase in targeted therapies for breast cancer, including in hormone receptor (HR) positive, HER2+ and triple-negative breast cancers (TNBC). The development of CDK4/6, PI3K and new SERDs in HR+ breast cancer, new HER2-targeted therapies (including small molecule inhibitors, ADCs and monoclonal antibodies) and Trop2-ADCs and PARP inhibitors for TNBC and BRCA-mutated cancers, respectively, has changes the way we treat patients with all breast cancer subtypes. These advances have improved patient outcomes and give clinicians more treatment options. For this Special Issue, we welcome original and review papers focused on targeted therapies in breast cancer, including novel rational combinations and strategies to overcome treatment resistance. While the issue is not focused on immunotherapy, works focused on combination strategies including immunotherapy and targeted therapies are also encouraged.

Guest Editors

Dr. Jennifer Diamond

University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, 12801 E 17th Ave, MS8117, Aurora, CO 80045, USA

Dr. Jennifer Richer

Department of Pathology, Anschutz Medical Campus, University of Colorado, Aurora, CO 80045, USA

Deadline for manuscript submissions

closed (31 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/95187

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)